
Ireland-headquartered drugmaker Shire (LSE: SHP) has recorded a rise in sales and earnings to deliver strong full-year 2013 financial results, pushing the firm’s shares up 1.8% to £31.99 in midday trading.
Product sales came in at $4,757 million, up 12% from $4,253 million in 2012, bringing total revenues to $4,934 million, up 9% from $4,527 million in 2012. The growth in product sales was offset by lower royalties and other revenues.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze